deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03456726

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Sponsor: Eisai Co., Ltd.

Conditions Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Interventions Tazemetostat
Updated 17 times since 2018 Last updated: Nov 18, 2022 Started: Apr 9, 2018 Primary completion: Dec 17, 2021 Completion: Dec 17, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma and is currently completed. Eisai Co., Ltd. leads this study, which shows 17 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2018 – ~Aug 2018 · 5 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Sep 2019 · 6 months · monthly snapshot~Sep 2019 – ~Feb 2020 · 5 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Jan 2023 · 11 months · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Feb 2022 — Jan 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Oct 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Dec 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  10. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  11. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Mar 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eisai Co., Ltd.
Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aomori, Japan , Bunkyo-ku, Japan , Chiba, Japan , Chuo-ku, Japan , Fukuoka, Japan , Hiroshima, Japan , Isehara, Japan , Kobe, Japan , Koto-ku, Japan , Kumamoto, Japan and 15 more locations